Evidence map›Paper›PMID 40796124›Full record

ReviewAnnual review of pharmacology and toxicology2026

Biased Signaling in Psychedelic Action.

Daniel Wacker, John D McCorvy

Abstract readReview
In one paragraph

Review in Annual review of pharmacology and toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Integrated 5-HTMolecular psychiatry · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Daniel WackerDepartments of Pharmacological Sciences, Neuroscience, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; email: Daniel.wacker@mssm.edu.
John D McCorvyDepartment of Cell Biology, Neurobiology, and Anatomy, Department of Pharmacology and Toxicology, Neuroscience Research Center, and Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; email: jmccorvy@mcw.edu.

Funding

Structural Studies and Drug Discovery Illuminate Serotonin PharmacologyR35GM133504 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Daniel Wacker · 2019 to 2026
$3.4M
Molecular Mechanisms of G protein-coupled Receptor Biased SignalingR35GM133421 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI John D McCorvy · 2019 to 2026
$3.3M
Enhancement of the endogenous opioid system by ketamineR01DA058681 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Lakshmi A Devi, LLOYD D FRICKER · 2023 to 2026
$2.3M
Structure-based Design of Selective Serotonin Biased Agonists as Chemical Probes for Psychedelic PotentialR01MH133849 · NIMH · MEDICAL COLLEGE OF WISCONSIN · PI John D McCorvy · 2023 to 2026
$2.1M
Investigations into 5-HT2A signaling mechanisms of psychedelic drugs for the treatment of stimulant use disorderR01DA061433 · NIDA · MEDICAL COLLEGE OF WISCONSIN · PI ADAM L. Halberstadt, John D McCorvy · 2024 to 2026
$1.5M
NIDA NIH HHS R01 DA058681NIDA NIH HHS R01 DA061433NIGMS NIH HHS R35 GM133421NIGMS NIH HHS R35 GM133504NIMH NIH HHS R01 MH133849
6 · The paper itself

Abstract

Psychedelics show tremendous promise for treating psychiatric disorders and other illnesses, including pain and migraine. Despite decades of research, there is uncertainty which signaling mechanisms are necessary for rapid-acting and durable therapeutic effects of psychedelics. Although activation of the serotonin 5-HT

Indexed as

HallucinogensReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor AgonistsSignal TransductionAnimalsHumansHallucinogensReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor Agonistsbiased agonismGPCR signalingpsychedelicspsychiatric disordersserotonin

Identifiers

PMID40796124
PMCPMC12928165

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.